Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReDUX4
NCT04003974Phase 2Completed
- Sponsor
- Fulcrum Therapeutics
- Start
- Aug 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Fulcrum Therapeutics. Started Aug 2019; status: completed.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT04003974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003974.